Vectofusin-1
Based on 1 Customer Validation
Vectofusin-1 is a histidine-rich cationic amphipathic peptide derived from the LAH4 (HY-P0311) peptide family, and also acts as a Viral entry enhancer. Vectofusin-1 promotes the adhesion and fusion of retroviral/lentiviral vectors with cell membranes during viral entry, thereby improving transduction efficiency. Vectofusin-1 potently enhances lentiviral transduction of cells.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.14%
- Fòrmula: C132H229N39O26
- Peso molecular:2778.48
-
Almacenamiento:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
Vectofusin-1 (12 μg/mL; 6 h) potently enhances the transduction efficiency of multiple lentiviral and retroviral pseudotypes in umbilical cord blood-derived hCD34+ hematopoietic stem/progenitor cells, resulting in a GFP+ cell proportion ranging from 57.5% to 79.4%, with no detectable cytotoxicity[1].
Vectofusin-1 (0-35 μg/mL; 5 days) enhances the transduction efficiency of GALVTR-LV in umbilical cord blood-derived hCD34+ hematopoietic stem/progenitor cells, with an EC50 of 6 μg/mL and a maximum average transduction efficiency of up to 67%[1].
Vectofusin-1 (0-100 μg/mL; overnight) has a median toxic concentration (TC50) of 60 μg/mL against umbilical cord blood-derived hCD34+ hematopoietic stem/progenitor cells, resulting in a 1-log safety index (TC50/EC50 = 10)[1].
Vectofusin-1 (12 μg/mL) effectively enhances the transduction efficiency of VSV-G-pseudotyped lentiviral vectors in umbilical cord blood-derived hCD34+ hematopoietic stem and progenitor cells (HSPCs), with the proportion of GFP-positive cells ranging from 76.2% to 82.7% in both total cell and subset analyses, which is comparable to the efficacy of Retronectin[2].
Vectofusin-1 (12 μg/mL) effectively enhances the transduction efficiency of VSV-G-pseudotyped lentiviral vectors in bone marrow-derived hCD34+ hematopoietic stem and progenitor cells (HSPCs); in analyses of total cells and subpopulations, the proportion of GFP-positive cells ranges from 69.8% to 74.8%, with a mean vector copy number (VCN) of 6.0 per cell, which is comparable to the efficacy of Retronectin[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB-Rag/γC immunodeficient mice (newborn pups)[1]
-
Dosage:12 μg/mL
-
Administration:ex vivo
-
Result:Detected equivalent numbers of hCD45+ human cells in peripheral blood, thymus, spleen, and bone marrow compared to untreated or Retronectin-treated cells.
Achieved engraftment of transduced GFP+ hCD45+ cells at least as robust as with Retronectin.
Observed active human thymopoiesis, with efficient transduction of immature CD3-low double-positive hCD4/hCD8 cells and mature CD3-high single-positive hCD4 and hCD8 T cells in the thymus.
Detected active human B lymphoid development (hCD19+ cells) in the spleen, which was efficiently transduced.
Detected and transduced human hematopoietic stem cells (hCD34+ hCD45+ cells), monocytes (hCD14+ cells), and granulocytes (hCD11b+ cells) in the bone marrow.
Chemical Information
-
Appearance Solid
-
Peso molecular 2778.48
-
Fòrmula C132H229N39O26
-
Color White to off-white
-
Sequence
Lys-Lys-Ala-Leu-Leu-His-Ala-Ala-Leu-Ala-His-Leu-Leu-Ala-Leu-Ala-His-His-Leu-Leu-Ala-Leu-Leu-Lys-Lys-Ala-NH2
-
Sequence Shortening
KKALLHAALAHLLALAHHLLALLKKA-NH2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (35.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Fenard D, et al. Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Mol Ther Nucleic Acids. 2013;2(5):e90. Published 2013 May 7. [Content Brief]
[2]. Piovan C, et al. Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes. Mol Ther Methods Clin Dev. 2017;5:22-30. Published 2017 Mar 8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.3599 mL | 1.7995 mL | 3.5991 mL | 8.9977 mL |
| 5 mM | 0.0720 mL | 0.3599 mL | 0.7198 mL | 1.7995 mL | |
| 10 mM | 0.0360 mL | 0.1800 mL | 0.3599 mL | 0.8998 mL | |
| 15 mM | 0.0240 mL | 0.1200 mL | 0.2399 mL | 0.5998 mL | |
| 20 mM | 0.0180 mL | 0.0900 mL | 0.1800 mL | 0.4499 mL | |
| 25 mM | 0.0144 mL | 0.0720 mL | 0.1440 mL | 0.3599 mL | |
| 30 mM | 0.0120 mL | 0.0600 mL | 0.1200 mL | 0.2999 mL |
Vectofusin-1 Related Classifications
HY-P11460 Related Classifications
Powered by Bioz
Keywords
- Vectofusin-1
- Vectofusin1
- Vectofusin 1
- Drug Derivative
- human CD34+ hematopoietic stem/progenitor cells
- lentiviral vectors
- BALB-Rag/γC mice
- activated human T lymphocytes
- γ-retroviral vectors
- RD114-TR-pseudotyped lentiviral vectors
- VSV-G pseudotyped lentiviral vectors
- bone marrow
- umbilical cord blood
- mobilized peripheral blood
- Inhibitor
- inhibitor
- inhibit